about
Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction.Study of proteomic changes associated with healthy and tumoral murine samples in neuroblastoma by principal component analysis and classification methods.Spot overlapping in two-dimensional maps: a serious problem ignored for much too long.Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line.PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma.Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cellsAngiogenesis and anti-angiogenesis in neuroblastoma.Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effectsImmunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.Fenretinide as an anti-angiogenic agent in neuroblastoma.Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma.Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment.Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells.Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastomaTumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.Angiogenesis in neuroblastoma.Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities.New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.Cloning and sequencing of isoform-specific regions of human Ca2+-independent protein kinase C (PKC)-encoding genes.Discovery of a novel glucose metabolism in cancer: The role of endoplasmic reticulum beyond glycolysis and pentose phosphate shunt.Ligand-targeted liposomal therapies of neuroblastoma.Targeted drug delivery and penetration into solid tumors.Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma.Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.A novel liposomal Clodronate depletes tumor-associated macrophages in primary and metastatic melanoma: Anti-angiogenic and anti-tumor effects.Anti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma.The Neuronal Pentraxin-2 Pathway Is an Unrecognized Target in Human Neuroblastoma, Which Also Offers Prognostic Value in Patients.Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switchingTherapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides.The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
P50
Q30536922-0B53A1C8-B527-4E3A-BF95-DFAF5A54A4D0Q31078437-538D6389-65EF-4B1F-B512-A186DE6424B8Q33214825-15951304-4677-4E39-8E38-D1B7BF69C9CEQ33252847-550CD21E-6D5A-45A5-AA2F-1AF6E002FC7EQ33721880-22F7B737-50FC-48BD-9277-275F02A39F07Q33721880-5DFF827B-661C-4FD1-9AFB-D88800912EBBQ33968452-F5299E98-D5D6-4A77-B9FB-D619252E63F7Q34591061-DCCACF80-D011-4010-AA4A-DFF3BA582A09Q35049970-A82E206F-D178-4B43-BE2A-BA709CABD53AQ35161323-30DEA621-2DDD-40B7-A4D1-BB6D33AC0622Q35184976-3A2DCD71-9899-4D86-BD84-5A84895A72ABQ35184989-D5036C3B-8492-4267-81FB-44F1F07533C7Q35185002-D1A680C7-8F3C-4258-BC4B-3FCCB44B66BDQ35185010-3FB2B48D-3344-4499-9611-348FBB790F6AQ35616838-C1A10DAF-36CA-427A-8588-B7CA01064E38Q35623435-B6C849DF-29FB-4DDD-98D0-5E7051D6AF48Q36009154-3EA0B753-E8D8-484E-A7F0-E0A1E6076F95Q36009168-CDF49591-9899-495B-9256-27583BDC05AEQ36151819-854A23AB-BBC5-46CA-B6FC-24E68F19770AQ36557133-C69DBFB2-3710-4799-BEB9-B2726ACFB107Q36748034-E3C9A650-312A-4594-B874-75A8ABF00879Q36845896-44E5B6A1-A161-4ACD-96E3-CD7CE58F669EQ37066071-5FFCDF11-ED66-4EF2-AD16-44E339F3E89FQ37834514-FDC45ABE-CC34-4E81-9793-7A375D455027Q38128317-C35B72AB-37AD-45B6-9A64-45464ABFC78CQ38332042-98D9AE90-DE45-4E56-BB36-94D4D364F115Q38805799-16122F36-61B3-4C68-B90B-979DDA5630B1Q38837839-0C162457-65C9-4486-97A5-C08A1744C6F2Q38842134-6E28CA12-6A61-4117-AE23-2E770F2CFA74Q38843502-3B487E9B-7C5C-4871-AC95-755967ABF267Q38868828-C999F0E4-926E-4753-91AC-9B5A0054B23FQ38886708-747362A5-B88B-4442-9E78-D72CFF586C7DQ38959374-581E8BAF-3D4C-4B58-9527-E3AB31E376CCQ38973832-DF819703-48AE-4E4D-8F4F-CFD293CDF6D2Q39136546-1E659AC7-6311-4418-87E2-BB1B835A98D1Q39616253-DD00C857-0FE4-4B5A-BB06-F7BFDC3B7A9FQ39646065-0842C7C4-B95B-4FBA-8040-7F2BBDDD8195Q39668506-D4DD3078-0942-4324-9AE7-E21B51AA8488Q39854389-F5A16DDC-B222-4426-ABB4-CAD76B602FD1Q39882024-97A3F537-F09F-4AB8-93AE-57C1C628E85E
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mirco Ponzoni
@ast
Mirco Ponzoni
@en
Mirco Ponzoni
@es
Mirco Ponzoni
@nl
Mirco Ponzoni
@sl
type
label
Mirco Ponzoni
@ast
Mirco Ponzoni
@en
Mirco Ponzoni
@es
Mirco Ponzoni
@nl
Mirco Ponzoni
@sl
prefLabel
Mirco Ponzoni
@ast
Mirco Ponzoni
@en
Mirco Ponzoni
@es
Mirco Ponzoni
@nl
Mirco Ponzoni
@sl
P1053
J-7713-2016
P106
P1153
7006558778
P21
P31
P3829
P496
0000-0002-6164-4286